Allain H, Bentué-Ferrer D, Saiag B, Belliard S, Thaminy S
Laboratoire de Pharmacologie Clinique, Faculté de Médecine, Rennes, France.
Therapie. 1993 Nov-Dec;48 Spec No:697-705.
The calcium antagonists (CA) which are at our disposal are a pharmacological class potentially active on the calcium homeostasis at the central nervous system level. Instead of reviewing the whole possibility of therapeutical potential targets, the authors review the 3 main possible and up-to-date impacts of these compounds: cerebral vasoactivity, neurotransmission, cell death. The actual lack of good clinical trials in those fields is stressed as well as the consequent necessity to stimulate the undertaking of such trials in humans in order to avoid to limit the use of CA in the only cardio-vascular spectrum.
我们现有的钙拮抗剂(CA)是一类在中枢神经系统水平上可能对钙稳态具有活性的药物。作者并未综述治疗潜在靶点的所有可能性,而是回顾了这些化合物的3种主要的、可能且最新的影响:脑血管活性、神经传递、细胞死亡。文中强调了这些领域目前缺乏良好的临床试验,以及因此有必要推动此类人体试验的开展,以避免将钙拮抗剂的使用局限于仅用于心血管领域。